SAB Biotherapeutics Files Definitive Proxy Statement
Ticker: SABSW · Form: DEF 14A · Filed: May 30, 2024 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | DEF 14A |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $6.30, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
SAB Biotherapeutics DEF 14A filed. Get ready for the shareholder meeting - important votes coming up.
AI Summary
SAB Biotherapeutics, Inc. filed a definitive proxy statement (DEF 14A) on May 30, 2024, for its annual meeting of stockholders. The company, formerly known as Big Cypress Acquisition Corp., is seeking shareholder approval for various matters related to its corporate governance and operations. The filing details the company's business, executive compensation, and director nominations.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions regarding company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: medium — Proxy statements can indicate upcoming significant corporate actions or changes in governance that may impact stock value.
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former company name
- 0000950170-24-066767 (filing_id) — Accession Number
- 20240530 (date) — Filing Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information required in a proxy statement for the annual meeting of stockholders, including details on matters to be voted upon.
When was this filing made with the SEC?
This filing was made with the SEC on May 30, 2024.
What was SAB Biotherapeutics, Inc. formerly known as?
SAB Biotherapeutics, Inc. was formerly known as Big Cypress Acquisition Corp.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc. is headquartered at 2100 East 54th Street North, Sioux Falls, SD 57104.
Filing Stats: 4,767 words · 19 min read · ~16 pages · Grade level 11.6 · Accepted 2024-05-30 17:15:05
Key Financial Figures
- $0.0001 — f record of our common stock, par value $0.0001 per share, and Series A Preferred Stock
- $6.30 — k basis, based on a conversion price of $6.30 per share and stated value of $1,000 pe
- $1,000 — of $6.30 per share and stated value of $1,000 per share. The voting of the Series A P
Filing Documents
- sabs_def14a_fy24agm.htm (DEF 14A) — 1286KB
- img2457068_0.jpg (GRAPHIC) — 13KB
- img2457068_1.jpg (GRAPHIC) — 625KB
- img2457068_2.jpg (GRAPHIC) — 268KB
- 0000950170-24-066767.txt ( ) — 2535KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 28 EXECUTIVE OFFICERS 31
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 32 EQUITY COMPENSATION PLAN INFORMATION 37 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 37 REPORT OF THE AUDIT COMMITTEE 39 WHERE YOU CAN FIND ADDITIONAL INFORMATION 39 OTHER MATTERS 39 SAB BIOTHERAPEUTICS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, JUNE 27, 2024 May 30, 2024 INFORMATION ABOUT SOLICITATION AND VOTING The accompanying proxy is solicited on behalf of the board of directors (the “Board”) of SAB Biotherapeutics, Inc. (“SAB”) for use at the SAB 2024 Virtual Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Thursday, June 27, 2024 10:00 AM Eastern Time, at www.virtualshareholdermeeting.com/SABS2024. References in the proxy statement to “we,” “us,” “our,” “the Company” or “SAB” refer to SAB Biotherapeutics, Inc. QUESTIONS AND ANSWERS ABOUT THE MEETING Q: Why am I receiving these materials? A: This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our Board for use at the Annual Meeting, and any postponements or adjournments thereof. The Annual Meeting will be held on June 27, 2024 at 10:00 AM Eastern Time, virtually at www.virtualshareholdermeeting.com/SABS2024. Stockholders are invited to attend the Annual Meeting and are requested to vote on the items of business described in this proxy statement. The proxy statement is being mailed on or about May 31, 2024 to all stockholders entitled to vote at the Annual Meeting. Q: What is the purpose of the meeting? A: At the Annual Meeting, stockholders will act upon the proposals described in this proxy statement. In addition, following the formal portion of the Annual Meeting, management will be available to respond to questions from stockholders. Q: What proposals are scheduled to be voted